Key person interview
Words of co-creation, words of symbiosis
Collection of key person interviews
We will tell you about people's passion for drug discovery.
Deliver new drugs to Underserved Therapeutic Areas. To that end, SymBio Pharmaceuticals' activities are supported not only by our employees, but also by many other people. We interviewed key people inside and outside the company about episodes of new drug development, past and future business prospects, and expectations for SymBio Pharmaceuticals. The passion of people spread around drug discovery. Please listen to the words that are born from there.
The "Key Person Interview Collection" is included to provide our stakeholders with information related to our company. Although it may contain information on ethical drugs and development products, it is intended to provide information to the press, shareholders, and investors, and is intended for promotion, advertising, medical advice, etc. It is not intended to be
■Dear Experts
-
NEW
for EB virus-positive lymphoma,
Expectations for the development of new treatmentsDepartment of Internal Medicine, Shimane University School of Medicine
Hematology and Oncology Professor
Mr. Ritsuro Suzuki -
The possibility of treatment with a combination of drugs
I want to expand through joint researchProfessor Emeritus, University of Tokyo
Head of Advanced Medical Research Center, Kobe Medical Industry Development Organization
University of Tokyo Faculty of Pharmaceutical Sciences Molecular Oncology Specially Appointed Researcher
Professor Toshio Kitamura -
Treatment options for relapsed or refractory DLBCL
I am very happy to have increasedDokkyo Medical University Saitama Medical Center
Department of Diabetes Endocrinology and Hematology Associate Professor
Professor Toru Kiguchi -
Save patients with excellent antiviral activity,
Expectations for development of brincidofovir injectionMemorial Sloan Kettering Cancer Center
Infectious disease department doctor
Weill Cornell Medical School Professor
Dr. Genoveva Papanicola -
overcoming development risks and financial crises
I would like to express my utmost respect for achieving profitability.JAFCO Investment (Asia Pacific) Ltd
President & CEO
Yoshiyuki Shibusawa -
Embracing a clear growth story,
desire to work hard togetherChairman of Well Investment Co., Ltd.
Waseda University Professor Emeritus, Doctor of Commerce
Mr. Shuichi Matsuda
■ SymBio Pharmaceutical members
-
Always identify Underserved Therapeutic Areas,
Agile global developmentCorporate Officer, Chief Medical Officer
Koji Fukushima -
We want to reach as many patients as possible.
With that in mind, we provide information on the web.
Real-lifeDirector of Marketing
Kenji Kikuchi -
Construction of distribution system for own sales,
And to achieve stable supplyGeneral Manager of Distribution Strategy Department
Susumu Umehara